Biotech startups in San Francisco, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Multiply Labs | San Francisco | Series B | $75.0M | 2026-10-06 |
| Chai Discovery | San Francisco | Series C | $400.0M | 2026-07-14 |
| Unlearn.AI | San Francisco | Series C | $50.0M | 2024-02-08 |
| Loyal | San Francisco | Series C | $100.0M | 2026-02-11 |
| Medra AI | San Francisco | Series A | $52.0M | 2025-12-11 |
| Incode Technologies | San Francisco | Series B | $220.0M | 2021-12-07 |
| Mithrl | San Francisco | Series A | $20.0M | 2026-09-15 |
| Probably Genetic | San Francisco | Series A | $12.0M | 2026-10-15 |
8 rows of the CSV in 5 of its 18 columns.
- The 396 biotech startups in San Francisco, United States have raised $14.6B in total.
- 87 of them closed their most recent round in the last 12 months, $2.4B combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Omabit's $2.0M seed round on 26 October 2026.
- Y Combinator is an investor in 34 of them, more than any other fund.
- Health care is the most common other sector, with 269 companies (68%).
- 49% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 1 to 10 employees (56% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
24 of 396| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Probably Genetic | Probably Genetic develops treatments aimed at improving the lives of patients with severe, complex diseases. | Artificial intelligence | Series A | $12.0M | 2026-10-15 | $22.9M | Y Combinator, Khosla Ventures, TenOneTen Ventures +2 | 11 to 50 | 2018 |
| Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| Mithrl | Mithrl is a software development company that builds custom NGS data workflows on demand. | Artificial intelligence | Series A | $20.0M | 2026-09-15 | $24.0M | Bonfire Ventures | 51 to 100 | 2023 |
| Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| Kopra Bio | Kopra Bio develops viral immunotherapy treatments to cure cancer. | Biotech | Seed | $9.1M | 2026-06-16 | $9.7M | Y Combinator, Pioneer Fund | 1 to 10 | 2024 |
| ParcelBio | ParcelBio develops RNA medicine delivery systems and therapeutic development platforms. | Biotech | Seed | $13.0M | 2026-05-07 | $13.5M | Y Combinator, Alumni Ventures, Pioneer Fund +2 | 1 to 10 | 2024 |
| LTZ Therapeutics | LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. | Biotech | Series B | $38.0M | 2026-05-06 | $125.0M | Qiming Venture Partners, Shunwei Capital, K2VC +1 | 11 to 50 | 2022 |
| Fermeate | Fermeate provides photomolecular fermentation technology that makes biomanufacturing more sustainable and efficient. | Biotech | Seed | $2.5M | 2026-04-27 | $2.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| TippingPoint Biosciences | TippingPoint Biosciences develops therapeutics that target genome packaging states in diseases such as cancer. | Biotech | Seed | $4.5M | 2026-03-31 | $4.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2022 |
| Numerion Labs | Numerion Labs develops artificial intelligence systems for drug discovery using deep learning algorithms. | Artificial intelligence | Series D | $19.8M | 2026-03-19 | $241.4M | Y Combinator, Khosla Ventures, Creative Destruction Lab +1 | 11 to 50 | 2012 |
| Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| Ligo Biosciences | Ligo Biosciences develops deep-learning models for enzyme design to lower the cost of chemical manufacturing. | Biotech | Seed | $500K | 2026-01-01 | $500K | Y Combinator | 1 to 10 | 2024 |
| 1849 Bio | 1849 Bio creates microbes that extract metals affordably from low-grade copper and gold ores. | Biotech | Seed | $500K | 2026-01-01 | $500K | Y Combinator | 1 to 10 | 2024 |
| Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals develops and commercializes therapeutics for rare and age-related diseases. | Biotech | Series B | $55.0M | 2025-12-16 | $142.0M | Sofinnova Investments, venBio Partners, Apollo Health Ventures | 1 to 10 | 2012 |
| Medra AI | Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. | Artificial intelligence | Series A | $52.0M | 2025-12-11 | $63.0M | PharmStars | 11 to 50 | 2021 |
| Artos | Artos is an AI document-drafting platform that turns life sciences data and reports into submission packages. | Artificial intelligence | Pre-seed | $500K | 2024-02-27 | $500K | Y Combinator, Pioneer Fund | 1 to 10 | 2023 |
| Unlearn.AI | Unlearn.AI uses AI, digital twins, and statistical methods to enable smaller, more efficient clinical trials. | Artificial intelligence | Series C | $50.0M | 2024-02-08 | $134.8M | Alumni Ventures, Insight Partners, 8VC +2 | 51 to 100 | 2017 |
| Aizon | Aizon provides a cloud-based SaaS platform that improves industrial processes in biotech and pharma. | Artificial intelligence | Series C | $20.0M | 2024-02-07 | $44.8M | 500 Global, FundersClub, Uncork Capital +2 | 101 to 250 | 2013 |
| Aiolos Bio | Aiolos Bio is a biotech company developing therapies for respiratory diseases and immune conditions. | Biotech | Series A | $245.0M | 2023-10-24 | $245.0M | RA Capital Management, Atlas Venture, Forbion Capital Partners +2 | 11 to 50 | 2023 |
| Incode Technologies Unicorn | Incode Technologies provides omnichannel biometric identity verification for real-life identity checks. | Biotech | Series B | $220.0M | 2021-12-07 | $257.1M | FJ Labs, SoftBank, Framework Ventures +2 | 501 to 1,000 | 2015 |
| Qualio | Qualio provides a quality management system for life sciences companies. | Biotech | Series B | $50.0M | 2021-05-25 | $66.1M | 500 Global, Tiger Global Management, Menlo Ventures +2 | 51 to 100 | 2012 |
| Atexto | Atexto provides voice data solutions that enable voice interfaces as alternatives to keyboards. | Artificial intelligence | Seed | $713K | 2019-12-02 | $1.1M | 500 Global, Start-Up Chile, Redwood Capital Partners +2 | 10,001 or more | 2018 |
Table 1. Biotech startups in San Francisco, United States: the 24 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 396.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 3 | Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| 4 | Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
| 5 | Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| 6 | Aeovian Pharmaceuticals | Aeovian Pharmaceuticals develops and commercializes therapeutics for rare and age-related diseases. | Biotech | Series B | $55.0M | 2025-12-16 | $142.0M | Sofinnova Investments, venBio Partners, Apollo Health Ventures | 1 to 10 | 2012 |
| 7 | Medra AI | Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. | Artificial intelligence | Series A | $52.0M | 2025-12-11 | $63.0M | PharmStars | 11 to 50 | 2021 |
| 8 | LTZ Therapeutics | LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. | Biotech | Series B | $38.0M | 2026-05-06 | $125.0M | Qiming Venture Partners, Shunwei Capital, K2VC +1 | 11 to 50 | 2022 |
| 9 | Mithrl | Mithrl is a software development company that builds custom NGS data workflows on demand. | Artificial intelligence | Series A | $20.0M | 2026-09-15 | $24.0M | Bonfire Ventures | 51 to 100 | 2023 |
| 10 | Numerion Labs | Numerion Labs develops artificial intelligence systems for drug discovery using deep learning algorithms. | Artificial intelligence | Series D | $19.8M | 2026-03-19 | $241.4M | Y Combinator, Khosla Ventures, Creative Destruction Lab +1 | 11 to 50 | 2012 |
Table 2. Biotech startups in San Francisco, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 34 | 9% | 9 | Probably Genetic, Multiply Labs, Kopra Bio |
| 2 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 7 | 2% | 3 | Probably Genetic, Numerion Labs, Loyal |
| 3 | SOSV | Venture capital firm | Princeton, United States | 7 | 2% | 3 | Farm Minerals, Fermeate, TippingPoint Biosciences |
| 4 | Alumni Ventures | Angel group | Manchester, United States | 6 | 2% | 1 | ParcelBio |
| 5 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 6 | 2% | 3 | Farm Minerals, Fermeate, TippingPoint Biosciences |
| 6 | Pioneer Fund | Startup accelerator | Toronto, Canada | 6 | 2% | 3 | Kopra Bio, ParcelBio, Angstrom AI |
| 7 | 500 Global | Startup accelerator | Palo Alto, United States | 5 | 1% | ||
| 8 | Felicis | Venture capital firm | Menlo Park, United States | 4 | 1% | ||
| 9 | RA Capital Management | Startup incubator | Boston, United States | 4 | 1% | ||
| 10 | Sofinnova Investments | Venture capital firm | Menlo Park, United States | 3 | 1% | 1 | Aeovian Pharmaceuticals |
| 11 | Lux Capital | Venture capital firm | New York, United States | 3 | 1% | ||
| 12 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 3 | 1% | ||
| 13 | Founders Fund | Venture capital firm | San Francisco, United States | 2 | 1% | 1 | Multiply Labs |
| 14 | 8VC | Venture capital firm | Austin, United States | 2 | 1% | ||
| 15 | FJ Labs | Micro VC fund | New York, United States | 2 | 1% |
Table 3. Biotech startups in San Francisco, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 269 | 68% | $11.8B |
| Software | 133 | 34% | $4.1B |
| Artificial intelligence | 99 | 25% | $2.6B |
| Hardware | 18 | 5% | $899.5M |
| Cybersecurity | 7 | 2% | $297.7M |
| Fintech | 5 | 1% | $434.2M |
| Energy | 5 | 1% | $225.1M |
| Education | 2 | 1% | |
| Commerce | 1 | 0% | $74.4M |
Table 4. Biotech startups in San Francisco, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in San Francisco, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 9 | 10% | $290.9M |
| September 2026 | 3 | 3% | $21.0M |
| August 2026 | 7 | 8% | $133.0M |
| July 2026 | 6 | 7% | $418.1M |
| June 2026 | 6 | 7% | $200.6M |
| May 2026 | 6 | 7% | $68.2M |
| April 2026 | 7 | 8% | $138.8M |
| March 2026 | 13 | 15% | $53.1M |
| February 2026 | 2 | 2% | $100.5M |
| January 2026 | 15 | 17% | $537.2M |
| December 2025 | 11 | 13% | $414.6M |
| November 2025 | 2 | 2% | $16.0M |
Table 6. Biotech startups in San Francisco, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 74 | 19% | $2.0B |
| 2025 | 65 | 16% | $1.5B |
| 2024 | 48 | 12% | $675.1M |
| 2023 | 31 | 8% | $581.2M |
| 2022 | 26 | 7% | $482.1M |
| 2021 | 31 | 8% | $3.8B |
Table 7. Biotech startups in San Francisco, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 128 | 33% |
| 2020 to 2022 | 65 | 17% |
| 2015 to 2019 | 112 | 29% |
| 2010 to 2014 | 54 | 14% |
| Before 2010 | 33 | 8% |
Table 8. Biotech startups in San Francisco, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 219 | 56% |
| 11 to 50 | 125 | 32% |
| 51 to 100 | 27 | 7% |
| 101 to 250 | 10 | 3% |
| 251 to 500 | 2 | 1% |
| 501 to 1,000 | 2 | 1% |
| 1,001 to 5,000 | 1 | 0% |
| 10,001 or more | 3 | 1% |
Table 9. Biotech startups in San Francisco, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in San Francisco, United States. On 16 November 2026 that is 396 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 24 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 396 rows: 99 have no round amount, 0 no city and 51 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in San Francisco, United States are on the list?
- 396, in the file dated 16 November 2026. 87 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 396 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.